Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda clinical programs — 393 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Cambridge, USA
Founded
1993
Employees
1,617
Programs
1179
Drugs
359
Patents
1436
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Takeda projects

393 ClinicalTrials.gov programs sponsored by Takeda.

Takeda has 393 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

393 programs

Clinical programs

Page 3 of 9

  1. Fazirsiran Injection

    Takeda

    Alpha1-Antitrypsin Deficiency

    phase 3 small molecule active

    3 trials

  2. Febuxostat

    Takeda

    Cardiovascular Disease

    phase 3 small molecule completed

    1 trial

  3. Febuxostat IR

    Takeda

    Gout

    phase 3 small molecule completed

    2 trials

  4. Fibrinogen (human) + thrombin (human) (TachoSil)

    Takeda

    Surgical Resection of Superficial Renal Tumour

    phase 3 other completed

    1 trial

  5. Flomoxef

    Takeda

    Urinary Tract Infection

    phase 3 small molecule terminated

    1 trial

  6. Fosrenol (Lanthanum Carbonate)

    Takeda

    Chronic Kidney Disease, Stage 5

    phase 3 small molecule completed

    1 trial

  7. GA-GCB (velaglucerase alfa)

    Takeda

    Gaucher Disease

    phase 3 mab completed

    1 trial

  8. GLASSIA

    Takeda

    Graft Versus Host Disease

    phase 3 mab terminated

    1 trial

  9. GLASSIA

    Takeda

    Alpha1-antitrypsin Deficiency

    phase 3 mab completed

    1 trial

  10. HM16/047

    Takeda

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  11. HYQVIA

    Takeda

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy

    phase 3 mab completed

    2 trials

  12. High Dose Colchicine (4.8 mg total dose)

    Takeda

    Gout

    phase 3 small molecule completed

    1 trial

  13. IBI363

    Takeda

    iO Resistant sqNSCLC

    phase 3 small molecule active

    1 trial

  14. IGI, 10%

    Takeda

    Multiple Myeloma

    phase 3 mab active

    1 trial

  15. IGSC 20% infusion

    Takeda

    Primary Immunodeficiency Disease

    phase 3 mab completed

    1 trial

  16. IXAZOMIB

    Takeda

    Relapsed or Refractory Systemic Light Chain Amyloidosis

    phase 3 small molecule terminated

    1 trial

  17. Icatibant

    Takeda

    Hereditary Angioedema

    phase 3 small molecule completed

    3 trials

  18. Icatibant

    Takeda

    Angiotensin Converting Enzyme Inhibitor Induced Angioedema

    phase 3 small molecule completed

    1 trial

  19. Icatibant

    Takeda

    Angioedema

    phase 3 small molecule completed

    1 trial

  20. Iduronate-2-sulfatase enzyme replacement therapy

    Takeda

    Mucopolysaccharidosis II

    phase 3 mab completed

    1 trial

  21. Idursulfase (idursulfase-IT [HGT-2310])

    Takeda

    Hunter Syndrome and Cognitive Impairment

    phase 3 small molecule active

    1 trial

  22. Immune Globulin Infusion (Human), 10%

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  23. Immune Globulin Intravenous (Human), 10%

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 small molecule completed

    2 trials

  24. Immune Globulin Intravenous (IGIV)

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  25. Immune Globulin Intravenous (human), 10%

    Takeda

    Multifocal Motor Neuropathy

    phase 3 mab completed

    1 trial

  26. Immune Globulin Subcutaneous (Human), 20%

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  27. Intranasal Fentanyl Spray (INFS)

    Takeda

    Break Through Pain

    phase 3 small molecule completed

    1 trial

  28. Ixazomib

    Takeda

    Relapsed Multiple Myeloma

    phase 3 small molecule completed

    1 trial

  29. Ixazomib Citrate

    Takeda

    Multiple Myeloma

    phase 3 small molecule completed

    2 trials

  30. KER-050-D301

    Takeda

    myelodysplastic neoplasms/syndromes (MDS)

    phase 3 small molecule active

    1 trial

  31. LDX

    Takeda

    ADHD

    phase 3 small molecule completed

    1 trial

  32. LDX 30 mg

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  33. Lanadelumab

    Takeda

    Angioedema

    phase 3 small molecule completed

    2 trials

  34. Lanadelumab

    Takeda

    Hereditary Angioedema (HAE)

    phase 3 small molecule completed

    2 trials

  35. Lanadelumab

    Takeda

    Hereditary Angioedema

    phase 3 small molecule completed

    1 trial

  36. Lansoprazole

    Takeda

    Stomach Ulcer

    phase 3 small molecule completed

    2 trials

  37. Lansoprazole and naproxen and aspirin

    Takeda

    Osteoarthritis

    phase 3 small molecule completed

    1 trial

  38. Lansoprazole microgranules suspension

    Takeda

    Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    1 trial

  39. Lapaquistat Acetate

    Takeda

    Dyslipidemia

    phase 3 small molecule completed

    2 trials

  40. Lapaquistat acetate

    Takeda

    Hypercholesterolemia

    phase 3 small molecule completed

    4 trials

  41. Lapaquistat acetate and atorvastatin

    Takeda

    Hypercholesterolemia

    phase 3 small molecule completed

    2 trials

  42. Lapaquistat acetate and current lipid-lowering treatment

    Takeda

    Hypercholesterolemia

    phase 3 small molecule terminated

    1 trial

  43. Lapaquistat acetate and lipid-lowering therapy

    Takeda

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial

  44. Lapaquistat acetate and rosuvastatin

    Takeda

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  45. Lapaquistat acetate and simvastatin

    Takeda

    Hypercholesterolemia

    phase 3 small molecule completed

    2 trials

  46. Lapaquistat acetate and stable statin therapy

    Takeda

    Hypercholesterolemia

    phase 3 small molecule terminated

    2 trials

  47. Leuprorelin

    Takeda

    Prostate Cancer

    phase 3 small molecule completed

    1 trial

  48. Leuprorelin SR

    Takeda

    Prostatic Neoplasms, Locally Advanced

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Takeda have?

393 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.